Current status: Answered by Jenni Minto on 14 May 2025
To ask the Scottish Government whether it will provide an update on how many NHS boards are considering offering givinostat, also known as duvyzat, to people with Duchenne muscular dystrophy in a fair and equitable manner.
It is a matter for Health Boards to consider the implementation of any new medicine to meet the needs of their local population. However, in response to concerns raised regarding access to givinostat in Scotland, the Cabinet Secretary has met with the four health boards who provide regional services across Scotland for children and adults with neuromuscular disorders, including Duchenne muscular dystrophy (DMD). He has asked them to set out their timelines and approaches to the families who have children with DMD in the next two weeks. In addition, the Chief Pharmaceutical Officer has been assured that the consultants have reviewed all those who eligible to ensure fair and equitable access across Scotland.